We are live on
!
Find out more
FC
Fairpointe Capital Portfolio holdings
AUM
$66.3M
1-Year Est. Return
101.32%
This Fund
S&P 500
This Quarter
Est. Return
+8.72%
1 Year Est. Return
+101.32%
3 Year Est. Return
+48.06%
5 Year Est. Return
+95.29%
10 Year Est. Return
–
AUM
$6.87B
AUM Growth
+$918M
(+15%)
Cap. Flow
+$404M
Cap. Flow
% of AUM
5.88%
Top 10 Holdings %
Top 10 Hldgs %
30.67%
Holding
79
New
4
Increased
35
Reduced
33
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$186M |
| 2 |
Alcoa
AA
|
+$148M |
| 3 |
PPO
POLYPORE INTERNATIONAL, INC
PPO
|
+$130M |
| 4 |
CTXS
Citrix Systems Inc
CTXS
|
+$104M |
| 5 |
TechnipFMC
FTI
|
+$87.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MOLXA
MOLEX INC CL-A
MOLXA
|
+$93.4M |
| 2 |
MOLX
MOLEX INC
MOLX
|
+$90.6M |
| 3 |
Boston Scientific
BSX
|
+$74M |
| 4 |
BLC
BELO CORP SER A
BLC
|
+$57.9M |
| 5 |
Southwest Airlines
LUV
|
+$50.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.22% |
| 2 | Industrials | 16.12% |
| 3 | Healthcare | 10.99% |
| 4 | Communication Services | 9.03% |
| 5 | Financials | 7.56% |
Similar funds
EFM
NI
UL
WSC
AGEC
CIA
FLSMF
OHS
Fairpointe Capital's Q4 2013 Portfolio in Review
As of Q4 2013, Fairpointe Capital held 79 positions worth $6.87B, up 15% from $5.95B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Fairpointe Capital deployed $404M of net new capital in Q4 2013, opening 4 new positions and adding to 35 existing holdings. Its largest new stake was Alcoa: 6,662,124 shares worth $170M.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 28% a quarter earlier, followed by Industrials and Healthcare.
On the sell side, the largest reduction was Boston Scientific, an estimated $74M trimmed.
- Fairpointe Capital's largest Q4 2013 buy was Alcoa: 6,662,124 shares worth $170M.
- Fairpointe Capital added most to Edwards Lifesciences in Q4 2013, an estimated $186M increase.
- Fairpointe Capital's biggest Q4 2013 reduction was Boston Scientific, cutting an estimated $74M.
- Fairpointe Capital fully exited MOLEX INC CL-A in Q4 2013, selling an estimated $93.4M.
- Fairpointe Capital's ten largest holdings make up 31% of its $6.87B portfolio in Q4 2013.
- Fairpointe Capital opened 4 new positions and closed 3 in Q4 2013.
- Fairpointe Capital's portfolio value rose 15% quarter-over-quarter to $6.87B.
Based on Fairpointe Capital's 13F filing for Q4 2013, filed 11 Feb 2014.